Skip to content

Cannabis: all studies

Page 218 of 288: studies 2,171 to 2,180 of 2,874, newest first. Back to the cannabis overview

Research

The use of cannabinoid therapy in treatment-refractory isolated REM sleep behavior disorder: a case report

Journal of Clinical Sleep Medicine March 25, 2025 Sahej Samra, Hrayr Attarian, R. Malkani

Current treatments for rapid eye movement sleep behavior disorder are not always effective and can lead to dose-limited adverse events, and new treatments are needed for this condition. We present a case of a patient with treatment-refractory isolated rapid eye movement sleep behavior disorder who had a dramatic and sustained improvement in dream enactment behaviors using oral tinctures...

Preliminary pharmacokinetic and psychophysical investigations after controlled oral and inhalative consumption of hexahydrocannabinol (HHC)

Scientific Reports March 24, 2025 Lisa Höfert, Benjamin Franz, Cedric Groß et al. 2 citations

The semi-synthetic cannabinoid hexahydrocannabinol (HHC) has become a highly discussed topic in forensic toxicology since 2022 due to its legal availability at this time and its psychoactive effects. This study aimed to investigate the pharmacokinetics, effects, and immunological detectability of HHC after oral (25 mg HHC fruit gum) and inhalative (three puffs from HHC vape) consumption with...

DOI: 10.1038/s41598-025-93931-4 (opens in new tab) Full text (opens in new tab) Pharmacokinetics Pharmacology Cannabinoid Saliva +1

Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.

Journal of Affective Disorders March 15, 2025 Thomas D Meyer, Maya Ibrahim, Lauren N Vale et al. 6 citations

Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic...

DOI: 10.1016/j.jad.2024.12.044 (opens in new tab) Full text (opens in new tab) Psychedelic drugs Behavioral health care Depression research Bipolar disorder +7

Prevalence and Correlates of Lifetime Ecstasy/MDMA Use Among Asian American and Pacific Islander Adult Populations in the United States, 2015–2020

Journal of Psychoactive Drugs March 3, 2025 Wayne Kepner, Patricia Dionicio, Katie Bailey et al. 3 citations

Little is known about ecstasy/MDMA use among Asian American and Pacific Islander populations. Research is important because AAPIs face unique cultural factors that may influence use. We estimated the prevalence and correlates of lifetime ecstasy/MDMA use based on a representative sample of US AAPI adults aged ≥18 from the 2015-2020 National Survey on Drug Use and Health. An estimated 5.1% of...

Psychosis and suicide attempt following a single use of delta-9-tetrahydrocannabiphorol: A case report.

Psychiatry and Clinical Neurosciences Reports March 1, 2025 Daniel Greer, Jennifer Atherton, Justina Girgis

Delta-9-tetrahydrocannabiphorol (Δ9-THCP) is a potent phytocannabinoid found naturally in the cannabis plant in small quantities. This cannabinoid is noted to potently bind to cannabinoid receptor 1 and cannabinoid receptor 2 and is reported to be highly psychoactive. A small amount of Δ9-THCP is found naturally, which led to its isolation and synthetic production. This isolate is beginning to...

DOI: 10.1002/pcn5.70060 (opens in new tab) Full text (opens in new tab) Thcp Psychosis Substance use Suicidality +1

Emerging medications and pharmacological treatment approaches for substance use disorders.

Pharmacology, Biochemistry, and Behavior March 1, 2025 Joel S Raymond, Alexander G Athanasopoulos, Connie J Badolato et al. 7 citations

Medications to treat substance use disorders (SUDs) remain suboptimal or, in the case of stimulants and cannabis, non-existent. Many factors have contributed to this paucity, including the biological complexity of addiction, regulatory challenges, and a historical lack of enthusiasm among pharmaceutical companies to commit resources to this disease space. Despite these headwinds, the recent...

The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample.

Biological Psychiatry Global Open Science March 1, 2025 Abigail E. Calder, Clifford Qualls, Gregor Hasler et al. 5 citations

The Hallucinogen Rating Scale (HRS) has been widely used to measure the subjective effects of psychedelics and other psychoactive substances. Its advantages include a basis in phenomenological interviews and clinical studies, straightforward items, and broad coverage of psychedelic effects. Previous studies have attempted to resolve its factor structure but were limited by small samples of...

DOI: 10.1016/j.bpsgos.2024.100436 (opens in new tab) Full text (opens in new tab) Consciousness studies Psychedelics hallucinogens Entheogens Psychometrics measurement +8

Psychosis in a Military Veteran in the Context of Hallucinogen Use: A Case Report.

Cureus February 19, 2025 Paria Parhami, Sydney E Moriarty, Jay Parikh et al.

N, N-dimethyltryptamine (DMT) is a potent hallucinogenic compound with increasing recreational use despite limited safety data. While DMT use has been linked to psychosis, delusional parasitosis as a specific manifestation remains unreported. We present a novel case of a 60-year-old female veteran with chronic post-traumatic stress disorder (PTSD), a history of major depressive disorder, past...

DOI: 10.7759/cureus.79308 (opens in new tab) Full text (opens in new tab) Substance-induced psychosis Drug-induced psychosis Hallucinogen-induced psychosis Substance-related psychosis +21

Quantitative natural language processing markers of psychoactive drug effects: A pre-registered systematic review

Journal of Psychopharmacology February 16, 2025 Sachin Ahuja, Farida Zaher, Lena Palaniyappan 4 citations

Psychoactive substances used for recreational purposes have mind-altering effects, but systematic evaluation of these effects is largely limited to self-reports. Automated analysis of expressed language (speech and written text) using natural language processing (NLP) tools can provide objective readouts of mental states. In this pre-registered systematic review, we investigate findings from...

Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use

British Journal of Pain February 11, 2025 Anne Baker, Stephanie Lake, Philippe Lucas et al. 7 citations

Psychedelic substances have shown preliminary efficacy for several neuropsychiatric disorders and are currently being investigated for chronic pain conditions. However, few studies have investigated outcomes of naturalistic psychedelic use among individuals with chronic pain, and none have assessed psychedelic-related changes in substance use patterns in this population. In a cross-sectional...